A historical cohort study to assess the safety and effectiveness of olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer

A histological cohort study to assess the safety and effectiveness of olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer - JGOG3026 RESPONSE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041422

Enrollment

300

Registered

2020-10-27

Start date

2020-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All patients with platinum-sensitive relapsed ovarian cancer who received olaparib monotherapy from January 2018 to July 2020.

Exclusion criteria

Exclusion criteria: 1. platinum-resistant relapsed ovarian cancer 2. stable or progressive disease after platinum-based chemotherapy for patients with platinum-sensitive relapsed ovarian cancer 3. patients who had already received a PARP inhibitor before recurrence 4. patients who received both olaparib and bevacizumab combination maintenance therapy.

Design outcomes

Primary

Measure	Time frame
Incidence of adverse events during olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer	—

Secondary

Measure	Time frame
Progression-free survival (PFS), PFS2, TFST, and OS in patients with platinum-sensitive relapsed ovarian cancer who received olaparib monotherapy.	—

Countries

Japan

Contacts

Public ContactKosuke Yoshihara

Niigata University Graduate School of Medical and Dental Sciences Obstetrics and Gynecology

yoshikou@med.niigata-u.ac.jp025-227-2320

Outcome results